Rebecca Suk Heist
Harvard University · 794 works · 29,435 citations · h-index 71
Top works
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
- Lung cancer
- Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non–Small-Cell Lung Cancer
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- Code Status Documentation in the Outpatient Electronic Medical Records of Patients with Metastatic Cancer
- Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
- Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis
- Depression and Survival in Metastatic Non–Small-Cell Lung Cancer: Effects of Early Palliative Care
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
- A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
- Circulating 25-Hydroxyvitamin D Levels Predict Survival in Early-Stage Non–Small-Cell Lung Cancer Patients